NCT04429711 is a NA clinical trial of Ivermectin Oral Product in COVID-19, sponsored by Sheba Medical Center.

Who is sponsoring NCT04429711?

NCT04429711 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT04429711?

Interventions in NCT04429711: Ivermectin Oral Product.

Is NCT04429711 still recruiting?

NCT04429711 is currently status unknown. Last updated 16 June 2020.

Last reviewed 2020-06-16 · How we verify

NCT04429711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19

Status unknown NA Last updated 16 June 2020

What this trial tests

NA trial testing Ivermectin Oral Product in COVID-19 in 100 participants. Status unknown.

Timeline

12 May 2020

Primary endpoint
30 September 2020

31 October 2020

Quick facts

Lead sponsor	Sheba Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	12 May 2020
Primary completion	30 September 2020
Estimated completion	31 October 2020
Sites	1 location across Israel

Drugs / interventions tested

Ivermectin Oral Product — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Sheba Medical Center

Who can join

Adults 18 to 80, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, et al · · 2021 · cited 102× · PMID 34318930 · DOI 10.1002/14651858.cd015017.pub2
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
Kaur H, Shekhar N, Sharma S, Sarma P, et al · · 2021 · cited 52× · PMID 33389725 · DOI 10.1007/s43440-020-00195-y
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA, Wagstaff KM. · · 2020 · cited 52× · PMID 32942671 · DOI 10.3390/cells9092100
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, et al · · 2021 · cited 48× · PMID 33038449 · DOI 10.1016/j.jconrel.2020.10.009
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype.
Marcolino MS, Meira KC, Guimarães NS, Motta PP, et al · · 2022 · cited 28× · PMID 35870876 · DOI 10.1186/s12879-022-07589-8
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM. · · 2021 · cited 26× · PMID 33341233 · DOI 10.1016/j.bbrc.2020.10.042
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
Scarabel L, Guardascione M, Dal Bo M, Toffoli G. · · 2021 · cited 12× · PMID 33476760 · DOI 10.1016/j.ijid.2021.01.035

Verify or expand the search:

Other trials of Ivermectin Oral Product

Trials testing the same drug.

NCT04405843 — Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial) · Phase 2, PHASE3 · completed
NCT03578679 — Treatment of Pediculosis (Head Lice) in Senegal · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04429711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 16 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04429711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing